Gynecological Cancers, Cancer Vaccines & Immunotherapy: Are We Near Elimination? In this video for #OncoDaily io, host Dr. Sergey Badalyan sits down with Dr. Giuseppe Caruso, gynecologic oncology consultant at the European Institute of #Oncology (IEO) IRCCS, Milan, Italy, for an in-depth discussion on the rapidly evolving role of #immunotherapy in gynecologic cancers.
The conversation explores how immunotherapy is transforming the treatment landscape of endometrial, cervical, ovarian, and vulvar cancers, moving from limited options like carboplatin and paclitaxel to a new era of checkpoint inhibitors, ADCs, PARP inhibitor combinations, and precision oncology.
Dr. Caruso provides a comprehensive overview of current standards of care and discusses key clinical trials including RUBY, NRG-GY018, DUO-E, ATTEND, and KEYNOTE-B96. He explains why immunotherapy has produced unprecedented results in endometrial cancer while ovarian cancer remains one of the biggest challenges gynaecological oncology.
They discussed:
Why ovarian cancer remains resistant to checkpoint blockade.
PARP inhibitor and immunotherapy combinations and ctDNA-guided treatment and liquid biopsy.
The growing importance of ADCs in gynecologic oncology.
Therapeutic cancer vaccines in cervical cancer. How AI may influence biomarker integration, pathology, imaging, and treatment selection.
Whether immunotherapy could eventually replace chemotherapy in selected patients.